Brad Welsh

Senior Counsel

Clients turn to Brad as a trusted advisor. Brad advises and represents clients in regulated industries, with a predominant focus on life sciences and healthcare. His practices consist of product liability litigation defense and commercial contracting and commercial operating advice. As a litigator, Brad has successfully defended complex mass tort claims. As a commercial advisor, he leverages his in-depth knowledge of the life sciences industry to lead complex commercial contracting initiatives.  Brad provides practical advice to small and mid-size companies aimed at achieving business objectives while minimizing legal risk and ensuring compliance with a variety of complex legal and regulatory obligations including but not limited to the Food, Drug, and Cosmetic Act; federal and state false claims acts; federal and state anti-kickback statutes; Foreign Corrupt Practices Act; Stark Law; Open Payments provision of the PPACA; state drug price transparency reporting requirements and the Lanham Act.

Prior to joining Kendall Law, Brad served as in-house counsel at a small pharmaceutical company where he helped to successfully commercialize the company’s first U.S. product. Working for an emerging company afforded Brad the ability to be involved in all aspects of commercial operations.  Brad has first-hand experience solving the complex legal, regulatory, and compliance problems faced by emerging companies.

Brad graduated, cum laude, from Temple University Beasley School of Law in 2013. While in law school, Brad acted as a Research Editor for the Temple Journal of Science, Technology, and Environmental Law.  He also served as a judicial intern for the Honorable Timothy J. Savage of the Eastern District of Pennsylvania. He is admitted to practice law in the Commonwealth of Pennsylvania and the State of New Jersey. Prior to his legal career, Brad obtained a graduate degree in Forensic Science and prior to that, he obtained his Bachelor of Science degree in Chemistry and worked as a chemist at a leading chemical manufacturer.

Notable Corporate Representations

• Representation of an international pharmaceutical company in nationwide product liability claims related to MRI contrast dyes.
  • Successfully excluded all of Plaintiff’s general causation expert testimony resulting in complete summary judgement for our client and resulting in the voluntary dismissal of almost all additional cases nationwide. Davis v. McKesson Corp., No. CV-18-1157-PHX-DGC, 2019 WL 3532179 (D. Ariz. Aug. 2, 2019).
  • Successfully opposed Plaintiff’s petition to create Multi-District Litigation (MDL). In re Linear Gadolinium-Based Contrast Agents Prod. Liab. Litig., 341 F.Supp.3d 1381 (U.S. Jud. Pan. Mult. Lit. 2018).

Individual, Start-Ups, and Small Business Representation

     With a robust background in both law and business, Brad brings practical legal and business judgment to his representation of individuals, start-ups, and small and mid-size companies. Drawing on his experience in regulated industries, life sciences, healthcare, commercial contracting, and litigation, Brad helps clients navigate complex legal and compliance issues while pursuing their business objectives.

Brad’s prior in-house counsel experience with an emerging pharmaceutical company gives him a practical understanding of business operations, risk management, contracting, compliance, and commercialization. He works with clients to identify legal risks, resolve disputes, and structure business relationships in a way that supports sustainable growth.

2022 Notable Publication

• Jamie Kendall, Brad Welsh & Paul DeVastey, FDA Preemption and Albrecht’s Progeny, 76 Food and Drug L.J. 579 (2022).